Performance of genotypic tropism testing in clinical practice using the enhanced sensitivity version of Trofile as reference assay: results from the OSCAR Study Group.

نویسندگان

  • Valentina Svicher
  • Roberta D'Arrigo
  • Claudia Alteri
  • Massimo Andreoni
  • Gioacchino Angarano
  • Andrea Antinori
  • Guido Antonelli
  • Patrizia Bagnarelli
  • Fausto Baldanti
  • Ada Bertoli
  • Marco Borderi
  • Enzo Boeri
  • Isabella Bonn
  • Bianca Bruzzone
  • Anna Paola Callegaro
  • Roberta Cammarota
  • Filippo Canducci
  • Francesca Ceccherini-Silberstein
  • Massimo Clementi
  • Antonella D'Arminio Monforte
  • Andrea De Luca
  • Antonio Di Biagio
  • Simona Di Gianbenedetto
  • Giovanni Di Perri
  • Massimo Di Pietro
  • Lavinia Fabeni
  • Giovanni Fadda
  • Massimo Galli
  • William Gennari
  • Valeria Ghisetti
  • Andrea Giacometti
  • Andrea Gori
  • Francesco Leoncini
  • Franco Maggiolo
  • Renato Maserati
  • Francesco Mazzotta
  • Valeria Micheli
  • Genny Meini
  • Laura Monno
  • Cristina Mussini
  • Silvia Nozza
  • Stefania Paolucci
  • Saverio Parisi
  • Monica Pecorari
  • Daniele Pizzi
  • Tiziana Quirino
  • Maria Carla Re
  • Giuliano Rizzardini
  • Rosaria Santangelo
  • Alessandro Soria
  • Francesca Stazi
  • Gaetana Sterrantino
  • Ombretta Turriziani
  • Claudio Viscoli
  • Vincenzo Vullo
  • Adriano Lazzarin
  • Carlo Federico Perno
چکیده

OBJECTIVE The goal of the OSCAR programme is to evaluate the performances of genotypic HIV-1 tropism testing in clinical practice using the enhanced sensitivity version of Trofile (ESTA) as reference-assay. METHODS HIV-1 coreceptor-usage was assessed using plasma samples from 406 HIV-1 infected patients by ESTA and by gp120 V3 population-sequencing followed by Geno2pheno (set at a False Positive Rate [FPR] of 10% and 5%). RESULTS ESTA was successful in 365 (89.9%) samples indicating R5 in 254 (69.6%), and DM/X4 in 111 (30.4% of samples (104 [28.5%] DM and 7 [1.9%] X4). Genotypic-testing successfully assessed viral tropism for all 406 samples, including the 41 with undetermined result by ESTA. Genotypic-tropism testing at a FPR of 5% and 10% was 81.1% and 78.4% concordant with ESTA, respectively. Despite a sensitivity of 48.7% and 55.9% at a FPR of 5% and 10%, respectively, a high concordance (specificity: 95.3% for FPR of 5% and 88.2% for FPR of 10%) between genotypic-tropism testing and ESTA was reached in the detection of R5-tropic viruses. CONCLUSION Our results are in line with other European studies, and support the routine use of genotypic tropism testing in clinical-settings for monitoring of HIV-1 infected patients candidate to or failing CCR5-antagonists.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Concordance between two phenotypic assays and ultradeep pyrosequencing for determining HIV-1 tropism.

There have been few studies on the concordance between phenotypic assays for predicting human immunodeficiency virus type 1 (HIV-1) coreceptor usage. The sensitivity of ultradeep pyrosequencing combined with genotyping tools is similar to that of phenotypic assays for detecting minor CXCR4-using variants. We evaluated the agreement between two phenotypic assays, the Toulouse tropism test (TTT) ...

متن کامل

Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment

BACKGROUND Determination of HIV-1 tropism is a pre-requisite to the use of CCR5 antagonists. This study evaluated the potential of population genotypic tropism tests (GTTs) in clinical practice, and the correlation with phenotypic tropism tests (PTTs) in patients accessing routine HIV care. METHODS Forty-nine consecutive plasma samples for which an original Trofile(TM) assay was performed wer...

متن کامل

Use of cellular HIV DNA to predict virologic response to maraviroc: performance of population-based and deep sequencing.

BACKGROUND A tropism test is required before administration of the antiretroviral drug maraviroc. However, plasma RNA testing is not possible in patients with undetectable plasma viral loads. Here we assess genotypic testing of cellular human immunodeficiency virus (HIV) DNA from peripheral blood mononuclear cells (PBMCs) to predict virologic responses in treatment-experienced patients beginnin...

متن کامل

Genotypic tropism testing by massively parallel sequencing: qualitative and quantitative analysis

BACKGROUND Inferring viral tropism from genotype is a fast and inexpensive alternative to phenotypic testing. While being highly predictive when performed on clonal samples, sensitivity of predicting CXCR4-using (X4) variants drops substantially in clinical isolates. This is mainly attributed to minor variants not detected by standard bulk-sequencing. Massively parallel sequencing (MPS) detects...

متن کامل

48 week outcomes of maraviroc-containing regimens following the genotypic or Trofile assay in HIV-1 failing subjects: the OSCAR Study.

This study assessed the 48-week efficacy of an antiretroviral therapy including maraviroc following the assessment of co-receptor tropism by use of Geno2Pheno algorithm or the Trofile phenotypic assay in failing treatment-experienced HIV-1 patients. This was a multicenter, randomized, open-label, non-inferiority trial. Treatment-experienced subjects with HIV-RNA ≥500 copies/mL were randomized (...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • The new microbiologica

دوره 33 3  شماره 

صفحات  -

تاریخ انتشار 2010